• Neuroligin 1 Loss Drives Repetitive Behaviors via D2-MSN Hyp

  2026-06-09

  This study uncovers how Neuroligin 1 deficiency in striatal D2 receptor-expressing medium spiny neurons (D2-MSNs) leads to autistic-like repetitive behaviors through PKC overactivation and neuronal hyperexcitability. These findings clarify cellular mechanisms underlying restricted and repetitive behaviors in autism spectrum disorder, offering new molecular intervention points for translational neuroscience.

• CX-4945 (Silmitasertib): Applied CK2 Inhibition in Cancer an

  2026-06-09

  CX-4945 (Silmitasertib) is redefining selective CK2 inhibition, powering both cancer and antiviral research with robust, reproducible protocols. This article delivers actionable workflows, troubleshooting strategies, and data-driven insights—bridging oncology and virology with confidence.

• Hemagglutinin mRNA Vaccine Protects Dairy Cows from H5N1

  2026-06-08

  This study demonstrates that a hemagglutinin-based mRNA vaccine delivered via lipid nanoparticles induces robust and durable protection against H5N1 influenza in lactating dairy cows. The results highlight the practical feasibility of mRNA platforms for veterinary applications and inform future vaccine strategies in livestock and zoonotic disease control.

• Otilonium Bromide: Applied Antimuscarinic Workflows in Resea

  2026-06-08

  Otilonium Bromide empowers precise modulation of muscarinic pathways in neuroscience and smooth muscle studies. This article delivers actionable protocols, advanced troubleshooting, and comparative insight—backed by APExBIO’s high-purity formulation—for robust cholinergic signaling research.

• AP20187: Chemical Inducer of Dimerization for Regulated Cell

  2026-06-07

  AP20187 is a synthetic, cell-permeable chemical inducer of dimerization widely used in regulated cell therapy and conditional gene expression. Its high purity, robust solubility, and validated in vivo efficacy make it a gold-standard tool for fusion protein dimerization and metabolic research.

• Flumequine: Redefining DNA Topoisomerase II Inhibition in Tr

  2026-06-06

  Explore how Flumequine, a selective DNA topoisomerase II inhibitor, transforms experimental precision and strategy for translational researchers. This thought-leadership article blends mechanistic insights with actionable guidance, drawing on in vitro cancer drug response paradigms and integrating workflow optimization, protocol recommendations, and a vision for next-generation DNA replication research.

• Entecavir (BMS200475): Mechanisms and Clinical Impact in HBV

  2026-06-05

  Explore the mechanistic depth and clinical significance of Entecavir in chronic hepatitis B virus therapy. This article offers a unique, evidence-driven analysis of its pharmacodynamics, resistance profile, and advanced applications, providing insights beyond standard protocol guidance.

• Ferroptosis Gene Signature and Atorvastatin in HCC Prognosis

  2026-06-05

  This study establishes a novel ferroptosis-related gene signature for predicting hepatocellular carcinoma (HCC) outcomes and identifies Atorvastatin as a promising therapeutic agent based on bioinformatic screening and experimental validation. The findings highlight new avenues for prognosis and ferroptosis-targeted therapy in HCC.

• Thymoquinone in Cardiotoxicity Research: Protocols & Innovat

  2026-06-04

  Thymoquinone, or 2-isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione, sets a new benchmark for modeling and mitigating doxorubicin-induced cardiotoxicity through Nrf2/HO-1 pathway activation and robust antioxidant action. This article delivers actionable workflows, troubleshooting strategies, and evidence-driven tips for maximizing research reproducibility with APExBIO's thymoquinone.

• L-Alanyl-L-Glutamine: Reliable Intestinal Barrier Support

  2026-06-04

  L-Alanyl-L-Glutamine (SKU B8228) addresses the instability and solubility challenges of standard glutamine in gastrointestinal research. It is best suited for workflows requiring stable, water-soluble glutamine supplementation to support intestinal mucosa and barrier function. It should not be used in protocols that require DMSO or ethanol solubility, or where long-term aqueous storage is unavoidable.

• LNP-mRNA Vaccine Targeting Chlamydia psittaci: Immune Protec

  2026-06-03

  A recent study demonstrates that lipid nanoparticle-delivered mRNA encoding the major outer membrane protein (MOMP) of Chlamydia psittaci induces robust protective immune responses in BALB/c mice. This work provides both a methodological framework and preclinical efficacy evidence, informing future RNA vaccine development against zoonotic respiratory pathogens.

• Optimizing Erythrocyte Lysis for Translational Osteogenic Re

  2026-06-03

  This thought-leadership article explores how advanced erythrocyte lysis strategies, particularly the use of APExBIO’s Red Blood Cell Lysis Buffer (K1169), are reshaping sample preparation workflows in translational bone and immunology research. By integrating mechanistic insights into osteoblastic differentiation, recent evidence on RUNX2/AMPK signaling, and practical protocol guidance, it provides strategic recommendations for researchers aiming to translate preclinical findings into robust, clinically relevant data.

• LY2603618: Deep Dive into Chk1 Inhibition and DNA Repair Dis

  2026-06-02

  Explore how LY2603618, a potent Chk1 inhibitor, uniquely disrupts DNA damage repair and cell cycle progression. This article provides advanced mechanistic insights and bridges the latest cGAS research with practical guidance for cancer research workflows.

• (-)-Blebbistatin in Force-Mode Cell Biology: Mechanistic Ins

  2026-06-02

  Explore how (-)-Blebbistatin, a non-muscle myosin II inhibitor, enables force-mode dependent chromatin and cytoskeletal investigations in living cells. This article provides new perspectives on experimental design and mechanobiology, distinct from standard cytoskeletal research narratives.

• KN-62: Applied Protocols for CaMKII Inhibition in Cell Signa

  2026-06-01

  KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine, stands out as a highly selective CaMKII inhibitor, enabling precise dissection of calcium-dependent pathways in metabolic, cancer, and neurobiological models. This guide translates advanced research into actionable workflows, troubleshooting strategies, and data-driven protocol refinements for maximizing reproducibility and insight.

448 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page